Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Peginterferon alfa-2a + Ribavirin in Chronic Hepatitis C
NCT00800748Phase 4Completed
- Sponsor
- Roche
- Start
- Feb 2006
- Primary completion
- Jan 2009
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV) (3 arms), sponsored by Roche. Primary endpoint: Sustained Virological Response at 72 weeks. Started Feb 2006; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00800748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800748.